Scarica l'app Stockscreener
32.29
0.40%
0.13
Pre-mercato:
31.98
-0.31
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
[144] Tango Therapeutics, Inc. SEC Filing - Stock Titan
Tango Therapeutics Announces Major Underwritten Equity Offering - TipRanks
Tango Therapeutics Prices $600 Million Stock Offering - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66 - Moomoo
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted - TradingView
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering - Stock Titan
Tango Therapeutics (TNGX) raises ~$566.5M via 18.17M shares and pre-funded warrants - Stock Titan
Insider sale notice — TNGX (NASDAQ:TNGX) reports planned share sales - Stock Titan
Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data - Investing.com
Tango Therapeutics stock hits all-time high at 32.69 USD By Investing.com - Investing.com India
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year - Yahoo Finance
Tango Therapeutics prices $600M upsized public offering - scanx.trade
Tango Therapeutics prices $600 million stock offering - Investing.com India
Tango Therapeutics prices $600 million stock offering By Investing.com - Investing.com India
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - The Manila Times
Tango Therapeutics Offering Prefunded Warrants to Purchase Up to 1.8M Shares at $29.999 Each >TNGX - Moomoo
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Tango Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX) - Seeking Alpha
Tango Therapeutics stock rockets 53% on pancreatic cancer data - grafa.com
TNGX Maintained by HC Wainwright & Co. -- Price Target Raised to $66 - GuruFocus
Tango Therapeutics stock hits all-time high at 32.69 USD - Investing.com
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $42 - GuruFocus
Tango Therapeutics stock surges on pancreatic cancer trial data - qz.com
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Barchart.com
Canaccord raises Tango Therapeutics stock price target on drug combo By Investing.com - Investing.com Nigeria
Canaccord raises Tango Therapeutics stock price target on drug combo - Investing.com
B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating - marketscreener.com
Tango Therapeutics Stock Soars 53% After Pancreatic Cancer Trial Stuns Wall Street - TIKR.com
Tango Therapeutics Shares Surge 53% on Promising Pancreatic Cancer Trial Data - International Business Times Australia
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are - Benzinga
Tango Therapeutics stock soars on promising pancreatic cancer data - CryptoRank
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’ - MSN
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer - BioCentury
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside - TradingView
Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant - Stock Titan
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):